BNTC insider transaction filings
Benitec Biopharma Inc. — 19 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-30. Screen BNTC transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-30 | 4 | BUCHI J KEVIN — Director | Gift (G): 51,813 @ $0 | EDGAR |
| 2026-05-28 | 4 | Friedman David Matthew — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-01-26 | 4 | Mates Sharon — Director | Grant/award (A): 31,500 (derivative) @ $0 | EDGAR |
| 2025-12-29 | 4 | SUVRETTA CAPITAL MANAGEMENT, LLC — Director, 10% owner Cowen Aaron — 10% owner Averill Master Fund, Ltd. — Director, 10% owner Averill Madison Master Fund, Ltd. — Director, 10% owner | Purchase (P): 42,600 @ $12.85 · Purchase (P): 7,400 @ $12.85 · Purchase (P): 14,320 @ $13.10 · Purchase (P): 2,516 @ $13.10 · Purchase (P): 65,800 @ $13.44 · Purchase (P): 11,587 @ $13.44 | EDGAR |
| 2025-12-22 | 4 | SUVRETTA CAPITAL MANAGEMENT, LLC — Director, 10% owner Cowen Aaron — 10% owner Averill Master Fund, Ltd. — Director, 10% owner Averill Madison Master Fund, Ltd. — Director, 10% owner | Purchase (P): 8,700 @ $11.24 · Purchase (P): 1,515 @ $11.24 · Purchase (P): 13,950 @ $11.48 · Purchase (P): 2,434 @ $11.48 · Purchase (P): 16,650 @ $12.08 · Purchase (P): 2,892 @ $12.08 | EDGAR |
| 2025-12-03 | 4 | Mehta Kishan — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2025-12-03 | 4 | Francis Peter — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2025-12-03 | 4 | Mates Sharon — Director | Grant/award (A): 3,500 (derivative) @ $0 | EDGAR |
| 2025-12-03 | 4 | Smith Edward F — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2025-12-03 | 4 | BUCHI J KEVIN — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2025-11-20 | 4 | Mukadam Sophie — Chief Operating Officer | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2025-11-20 | 4 | Banks Jerel A. — Chief Executive Officer, Director | Grant/award (A): 450,000 (derivative) @ $0 | EDGAR |
| 2025-11-20 | 4 | Boston Megan — Chief Financial Officer, Director | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2025-11-10 | 4 | SUVRETTA CAPITAL MANAGEMENT, LLC — Director, 10% owner Averill Madison Master Fund, Ltd. — Director, 10% owner Averill Master Fund, Ltd. — Director, 10% owner Cowen Aaron — 10% owner | Purchase (P): 730,370 @ $13.50 · Purchase (P): 751,111 @ $13.50 | EDGAR |
| 2025-11-07 | 4 | Mates Sharon — Director | Grant/award (A): 28,517 (derivative) @ $0 | EDGAR |
| 2025-04-02 | 4 | SUVRETTA CAPITAL MANAGEMENT, LLC — Director, 10% owner Averill Madison Master Fund, Ltd. — Director, 10% owner Averill Master Fund, Ltd. — Director, 10% owner Cowen Aaron — 10% owner | Purchase (P): 9,503 @ $12.63 · Purchase (P): 1,267 @ $12.63 · Purchase (P): 5,057 @ $13.22 · Purchase (P): 670 @ $13.22 | EDGAR |
| 2025-03-28 | 4 | SUVRETTA CAPITAL MANAGEMENT, LLC — Director, 10% owner Averill Madison Master Fund, Ltd. — Director, 10% owner Averill Master Fund, Ltd. — Director, 10% owner Cowen Aaron — 10% owner | Purchase (P): 793,800 @ $13 · Purchase (P): 106,200 @ $13 | EDGAR |
| 2025-03-13 | 4 | BUCHI J KEVIN — Director | Gift (G): 103,626 @ $0 · Gift (G): 103,626 @ $0 | EDGAR |
| 2025-03-03 | 4 | BUCHI J KEVIN — Director | Option exercise (M): 51,813 @ $3.86 · Option exercise (M): 51,813 (derivative) @ $0 | EDGAR |
Recent 8-K events — Benitec Biopharma Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-05-29 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-02 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-11-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-07 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-03 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-22 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-12 | 8-K | 4.02 — Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review | EDGAR |
| 2025-07-09 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=BNTC returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →